Drug Type Antibody drug conjugate (ADC) |
Synonyms BG-C477 |
Target |
Action antagonists, inhibitors |
Mechanism CEACAM5 antagonists(Carcinoembryonic antigen related cell adhesion molecule 5 antagonists), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 03 Oct 2024 | |
Advanced Malignant Solid Neoplasm | Phase 1 | China | 03 Oct 2024 | |
Advanced Malignant Solid Neoplasm | Phase 1 | Australia | 03 Oct 2024 | |
Advanced Malignant Solid Neoplasm | Phase 1 | New Zealand | 03 Oct 2024 | |
Colorectal Cancer | Preclinical | China | 29 Apr 2025 | |
Lung Cancer | Preclinical | China | 29 Apr 2025 | |
Pancreatic Cancer | Preclinical | China | 29 Apr 2025 | |
Stomach Cancer | Preclinical | China | 29 Apr 2025 |